Morgan Stanley reiterated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report issued on Wednesday morning, Price Targets.com reports.
Several other analysts have also recently issued reports on HIK. Peel Hunt reissued a hold rating and issued a GBX 2,460 ($33.27) target price on shares of Hikma Pharmaceuticals in a research note on Thursday, November 4th. JPMorgan Chase & Co. reiterated an overweight rating on shares of Hikma Pharmaceuticals in a report on Monday, January 17th. Barclays decreased their price objective on shares of Hikma Pharmaceuticals from GBX 3,000 ($40.57) to GBX 2,800 ($37.86) and set an overweight rating for the company in a report on Wednesday. Citigroup restated a buy rating and issued a GBX 2,880 ($38.95) price objective on shares of Hikma Pharmaceuticals in a report on Monday, November 1st. Finally, Peel Hunt reaffirmed a hold rating and issued a GBX 2,460 ($33.27) target price on shares of Hikma Pharmaceuticals in a research report on Thursday, November 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Buy and an average target price of GBX 2,642 ($35.73).
LON HIK opened at GBX 1,965.50 ($26.58) on Wednesday. The stock’s 50-day simple moving average is GBX 2,124.01 and its two-hundred day simple moving average is GBX 2,333.09. Hikma Pharmaceuticals has a twelve month low of GBX 1,965 ($26.57) and a twelve month high of GBX 2,703 ($36.55). The company has a market capitalization of £4.55 billion and a price-to-earnings ratio of 13.25. The company has a quick ratio of 1.17, a current ratio of 2.04 and a debt-to-equity ratio of 40.47.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals.
Read More
Want More Great Investing Ideas?